

I. AMENDMENT

In the Claims:

The following listing of claims will replace all prior versions and listings of the claims in the application:

Listing of the Claims:

1. (cancelled).
2. (previously presented) A method for reducing an oxytocin-mediated action in a subject comprising administering to the subject an amount of thiazolidinedione effective to reduce the oxytocin-mediated action in the subject, wherein the oxytocin-mediated action is induction of labor in a pregnant subject, induction of uterine cramps, induction of milk letdown, or induction of prostaglandin release.
3. (original) The method of claim 2, wherein the oxytocin-mediated action is induction of labor in a pregnant subject.
4. (original) The method of claim 2, wherein the oxytocin-mediated action is induction of uterine cramps.
5. (original) The method of claim 2, wherein the oxytocin-mediated action is induction of milk letdown.
6. (original) The method of claim 2, wherein the oxytocin-mediated action is induction of prostaglandin release.
7. (original) The method of claim 2, wherein the subject is a mammal.
8. (previously presented) The method of claim 2, wherein the thiazolidinedione is troglitazone.

9. (currently amended) The method of claim 2, wherein the thiazolidinedione is pioglitazone, or BRL49653, ~~or a compound related to troglitazone~~.
10. (original) The method of claim 2, wherein the thiazolidinedione is dispersed in a pharmacologically acceptable form.
11. (original) The method of claim 10, wherein said thiazolidinedione is administered locally.
12. (original) The method of claim 10, wherein said thiazolidinedione is administered parenterally.
13. (original) The method of claim 12, wherein said thiazolidinedione is administered intravenously.
14. (original) The method of claim 11, wherein the thiazolidinedione is administered intravaginally.
15. (previously presented) The method of claim 2, further comprising administering a tocolytic agent.
16. (original) The method of claim 15, wherein said tocolytic agent comprises a beta-mimetic, magnesium sulfate, a prostaglandin inhibitor, or a calcium-blocking agent.
17. (original) The method of claim 16, wherein the prostaglandin inhibitor is indomethacin.
18. (original) The method of claim 17, wherein the calcium-blocking agent is nifedipine.
19. (original) The method of claim 15, wherein the tocolytic agent and thiazolidinedione are administered simultaneously.

20-21. (cancelled).